Oral HRS-7535 Lowered A1c in Trial
Nonpeptide oral agent requires no fasting administration.
-
By
-
Kathryn Wighton
-
June 5, 2026
-
-
1
Oral HRS-7535 significantly reduced hemoglobin A1c levels in patients with type 2 diabetes inadequately controlled by metformin.
-
2
The trial involved 194 patients and demonstrated that HRS-7535 doses of 60 mg and 90 mg provided similar glycemic control.
-
3
Patients receiving HRS-7535 achieved greater reductions in fasting plasma glucose and postprandial glucose compared to placebo.
-
4
Gastrointestinal adverse events were common but mostly mild or moderate, with higher rates in the 60-mg dose group.
-
5
The study's findings may not directly apply to Western populations due to differences in body mass index and diabetes characteristics.
